-

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Joe Morrissey, Interim Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd, 2025 at 10:00 a.m. ET.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at https://www.organon.com/investor-relations/events-and-presentations/.

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Contacts

Media Contacts:

Felicia Bisaro
(646) 703-1807

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Industry:

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB
Release Summary
Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.
Release Versions
English

Contacts

Media Contacts:

Felicia Bisaro
(646) 703-1807

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Social Media Profiles
Organon Facebook
Organon Instagram
Organon LinkedIn
Organon Twitter
More News From Organon & Co.

Organon Announces Quarterly Dividend

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h...

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Presents VTAMA (tapinarof) cream, 1% Analysis of Phase3 Pooled Data Showing Early Consistent Improvements in Eczema Patients Across Age Groups...

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will...
Back to Newsroom